drugset / Trial / NCT04441671
Oral Pyrophosphate Absorption in PXE Disease
Phase 2
Withdrawn
Tampere University Hospital
Hungarian Academy of Sciences · collabUMC Utrecht · collab
NaSingle-groupOpen-labelTreatment
Summary
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be provided for healthy controls and PXE-patients both fasting and with standard meal intake.
Timeline
- Start
- 2020-12-08
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Outcome
Outcome not reported
Stopped: “Withdrawn”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disodium Pyrophosphate | Unknown | 30 mg/kg | Oral |
| Subject | Disodium Pyrophosphate | Unknown | 50 mg/kg | Oral |